Pharsight

1. List of Kybella drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8242294	KYTHERA BIOPHARMS	Synthetic bile acid compositions and methods	May, 2028 (5 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846066	KYTHERA BIOPHARMS	Methods and related compositions for reduction of fat and skin tightening	Feb, 2025 (2 years from now)
US8298556	KYTHERA BIOPHARMS	Methods and related compositions for the non-surgical removal of fat	Aug, 2025 (2 years from now)
US7622130	KYTHERA BIOPHARMS	Methods and compositions for the non-surgical removal of fat	Dec, 2027 (4 years from now)
US7754230	KYTHERA BIOPHARMS	Methods and related compositions for reduction of fat	Dec, 2027 (4 years from now)
US8546367	KYTHERA BIOPHARMS	Synthetic bile acid compositions and methods	Feb, 2028 (5 years from now)
US9949986	KYTHERA BIOPHARMS	Synthetic bile acid compositions and methods	Feb, 2028 (5 years from now)
US9636349	KYTHERA BIOPHARMS	Synthetic bile acid compositions and methods	Feb, 2028 (5 years from now)
US9522155	KYTHERA BIOPHARMS	Synthetic bile acid compositions and methods	Feb, 2028 (5 years from now)
US8461140	KYTHERA BIOPHARMS	Synthetic bile acid compositions and methods	Feb, 2028 (5 years from now)
US8883770	KYTHERA BIOPHARMS	Synthetic bile acid compositions and methods	Feb, 2028 (5 years from now)
US8653058	KYTHERA BIOPHARMS	Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits	Mar, 2030 (7 years from now)
US8101593	KYTHERA BIOPHARMS	Formulations of deoxycholic acid and salts thereof	Mar, 2030 (7 years from now)
US8367649	KYTHERA BIOPHARMS	Formulations of deoxycholic acid and salts thereof	Mar, 2030 (7 years from now)
US10500214	KYTHERA BIOPHARMS	Formulations of deoxycholic acid and salts thereof	Mar, 2030 (7 years from now)

Market Authorisation Date: 29 April, 2015

Treatment: Method for reduction of submental fat; Improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults by means of reducing submental fat volume as described in the approved labeling

Dosage: SOLUTION;SUBCUTANEOUS